October 4, 2018 06:41 AM EDT
Financing
Deals

Black­stone bags Clarus, stak­ing out a grow­ing PhI­II niche for it­self in a rapid­ly chang­ing bio­phar­ma in­dus­try

John Carroll

Editor & Founder

Black­stone likes life sci­ences. And now it’s div­ing in deep.

The pri­vate eq­ui­ty gi­ant has com­plet­ed a deal to buy Clarus, a busy life sci­ences …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Apol­lo makes a deal worth up to $926M; Abeona re­sub­mits gene ther­a­py

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times